CCR5 and cancer: Due to the overexpression of CCR5 in several cancers, pyrimidine small‐molecule CCR5 inhibitors, namely maraviroc and vicriviroc, and a monoclonal anti‐CCR5 antibody, namely leronlimab, which were primarily used against human immunodeficiency virus (HIV), have been repurposed in clinical trials as cancer treatment.103